Bedel Financial Consulting, Inc. Incyte Corp Transaction History

Bedel Financial Consulting, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$66.18 - $83.18 $3,904 - $4,907	-59 Closed	0 $0
Q2 2020 Jul 14, 2020	SELL	$74.18 - $108.93 $222 - $326	-3 Reduced 4.84%	59 $6,000
Q1 2020 May 06, 2020	BUY	$63.18 - $85.97 $189 - $257	3 Added 5.08%	62 $5,000
Q1 2018 May 03, 2018	BUY	$83.06 - $100.98 $4,900 - $5,957	59 New	59 $5,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Bedel Financial Consulting, Inc., based on Form 13F filings with the SEC.

Stay updated on Bedel Financial Consulting, Inc. with notifications on news.